South London and Maudsley NHS Foundation Trust

DOVE TAKES ACTION AGAINST ONE OF THE BIGGEST THREATS TO KIDS' MENTAL HEALTH TODAY

Retrieved on: 
Tuesday, May 9, 2023

Over 8 in 10 youth mental health specialists say social media is fuelling a mental health crisis among young people.

Key Points: 
  • Over 8 in 10 youth mental health specialists say social media is fuelling a mental health crisis among young people.
  • Alongside singer/songwriter Self Esteem, Dove is partnering with Parenting Mental Health, Global Action Plan, 5Rights, Girlguiding to take action to support young people's mental health.
  • Dove is bringing together NGO partners Parenting Mental Health, Global Action Plan, 5Rights, and Girlguiding to provide access to mental health resources for young people, and work to make social media safer for kids.
  • The new 2023 Dove Self-Esteem Project Research for Kids Online Safety found:
    Over 8 in 10 youth mental health specialists say social media is fuelling a mental health crisis among young people.

Clinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion Diagnostics

Retrieved on: 
Thursday, December 15, 2022

Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.

Key Points: 
  • Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.
  • The clinical evaluation comprising 226 Clozapine-treated patients has found strong correlations between the standard lab venous method and HemoScreen's capillary and venous assays.
  • This study, which is being published in the Journal of Psychiatric Research, concluded HemoScreen to be a viable fit for finger-prick companion diagnostics, with the potential to substantially enhance treatment enrollment and adherence.
  • "HemoScreen offers a portable, quick and accurate alternative to the current venous blood non-portable methods of clozapine monitoring, and from a single drop of either capillary or venous blood.

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 3, 2022

Research and development (R&D) expenses were $14.0 million for the three months ended 30 September 2022, compared with $12.2 million during the same period in 2021.

Key Points: 
  • Research and development (R&D) expenses were $14.0 million for the three months ended 30 September 2022, compared with $12.2 million during the same period in 2021.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (12.00pm UK) on 3 November 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Third Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Retrieved on: 
Thursday, August 4, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (13.00 UK) on 4 August 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Second Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

Retrieved on: 
Tuesday, May 10, 2022

George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.

Key Points: 
  • George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.
  • R&D expenses were $15.4 million for the three months ended 31 March 2022, compared with $6.9 million during the same period in 2021.
  • The COMPASS Pathways management team will host a conference call at 1.00pm UK (8.00am ET) on 10 May 2022.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

Retrieved on: 
Monday, May 9, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults.
  • This will be the first ever mechanistic study of psilocybin in autistic adults.
  • Professor Grainne McAlonan, IoPPN, said: I am delighted that COMPASS Pathways is supporting our investigations into the brain science of neurodiversity.
  • Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: We are pleased to fund this innovative research, the first of its kind using psilocybin in autistic adults.

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

Retrieved on: 
Thursday, March 24, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.
  • We are grateful to be able to play a part in this, and to be working with SLaM and the IoPPN, UK leaders in patient care and research in mental health.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  • The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings is the premier centre for mental health and related neurosciences research in Europe.

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Retrieved on: 
Tuesday, January 4, 2022

The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.

Key Points: 
  • The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.
  • The participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29).
  • There were no serious adverse events and COMP360 psilocybin was found to be well-tolerated with no clinically-relevant negative effects on cognitive function.
  • Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: This study was an early part of our clinical development programme for COMP360 psilocybin therapy.

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

Retrieved on: 
Wednesday, August 11, 2021

This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic.

Key Points: 
  • This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic.
  • We are well-positioned for recruitment to phase III, pending results from the phase IIb study, which are expected later this year.
  • The call will also be webcast on the investors section of the COMPASS Pathways website ( ir.compasspathways.com ) and archived for 30 days.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK

Retrieved on: 
Monday, July 5, 2021

The three parties are keen to collaborate on a multi-year partnership that reflects their commitment to delivering innovation in mental health care.

Key Points: 
  • The three parties are keen to collaborate on a multi-year partnership that reflects their commitment to delivering innovation in mental health care.
  • By combining our strengths in biomedical research, clinical trials, clinical care, translational science, training, and digital innovation, we can create a world-class centre of excellence in mental health.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  • South London and Maudsley NHS Foundation Trust is a large and complex multi-site provider of mental health services providing the widest range of NHS mental health services in the UK.